CATEGORY

Oligonucleotides

Oligonucleotide is a therapeutic class which is highly specific to it target and efficient drug delivery

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Oligonucleotides.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo
Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Oligonucleotides Suppliers

    Oligonucleotides Supplier

    Find the right-fit oligonucleotides supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    Catalent Inc.
    Location
    Jackson, Mississipi
    Duns number
    3862211
    D&B SER Rating
    dnb logo

    Up to 3 months

    1 9
    1
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile
    Company and Sector Performance
    33
    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    30
    Social
    26
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    34
    Human rights
    32
    Community Environment
    15
    Corporate governance
    56
    Human resources
    26
    Security Scorecard
    79
    Threat indicators
    A
    91
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    F
    52
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    D
    62
    Application Security
    Detecting common website application vulnerbilities
    A
    100
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    A
    100
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    90
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked
    Industry Comparison
    catalent.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    0
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    0
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    0
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    0
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    21
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Oligonucleotides market report transcript

    Global Market Overview on Oligonucleotides

    More than 100 Oligonucleotides are currently under clinical trials and are moving towards regulatory approval. As they reach the market, demand for manufacturing capacity will increase forcing CMOs to expand .Global oligonucleotide CMO market is expected to grow at about 25 percent and reach a value of $550 million by  2020.

    Supply Demand

    Antisense oligonucleotides account for the major type of oligonucleotide currently in clinical trials. 83 out of the 142 ongoing clinical trials are antisense oligonucleotides.Currently there are 4-5 major CMOs in the market and they may not be able to support the growing demand once all drugs lined up for regulatory approval get market authorization

    More than 100 Oligonucleotides are currently under clinical trials and are moving towards regulatory approval. As they reach the market, demand for manufacturing capacity will increase forcing CMOs to expand

    • Oligonucleotides are regarded as the next big group of  therapeutics after small molecule and biologics. This is mainly due to their promise of low drug development cost and ability to reach targets that conventional small molecule drugs cannot achieve
    • Antisense oligonucleotide therapeutics  are currently the most promising class of oligonucleotides that have seen more success within the category
    • Challenges currently faced by oligonucleotide therapeutics include regulatory complexity, effective delivery of oligonucleotides, etc.
    • Although the number of oligo drugs in pipeline may be small as compared to small molecule and biologics, they still offer huge market potential

    Market Overview – Supply Demand

    Oligonucleotide API market has seen the demand accelerate and the market is growing at about 20-30% a year and this could expand further when these drugs are commercialized

    Supply

    • Supply market is very small at present since there are only four drugs in the market
    • Currently there are 4-5 major CMOs in the market and they may not be able to support the growing demand, once all drugs lined up for regulatory approval get market authorisation
    • All oligo API manufacturing CMOs have planned expansion of their existing facility or entered into joint ventures to construct a new manufacturing facility

    Demand

    • Demand is expected to increase many folds in the near future
    • With more drugs entering the market, there will be increased reliance on CMOs for their manufacturing expertise and experience
    • Well known CMOs with many years of experience in this space many be more sought after
    • Due to lack of capacity CMOs who are next in line with a good track record may also be considered

    Market Trends – Oligonucleotide API

    • In November 2017, RiboBio and GE Healthcare entered into a Strategic Partnership to build an Oligonucleotide CRO/CMO facility
    • ST Pharm announced the construction of its new oligo manufacturing unit in Korea. This plant is said to be operational by 2019
    • Similarly, GeneDesign a subsidiary of Ajinomoto announced that it will establish a new plant for Oligo API manufacturing in Japan, expected to be operational by 2019
    • Nitto Denko Avecia in July 2017 expanded their Oligonucleotide API manufacturing facility in Massachusetts by 2000 square feet. The facility is capable of producing oligonucleotide API capacity up to 1.8 molecular weight (mol)
    • In July 2017, CordenPharma International and GE Healthcare's Dharmacon business have entered a strategic collaboration to create end-to-end solution for oligonucleotide-based drug discovery